We noted you are experiencing viewing problems
-
Check with your IT department that JWPlatform, JWPlayer and Amazon AWS & CloudFront are not being blocked by your network. The relevant domains are *.jwplatform.com, *.jwpsrv.com, *.jwpcdn.com, jwpltx.com, jwpsrv.a.ssl.fastly.net, *.amazonaws.com and *.cloudfront.net. The relevant ports are 80 and 443.
-
Check the following talk links to see which ones work correctly:
Auto Mode
HTTP Progressive Download Send us your results from the above test links at access@hstalks.com and we will contact you with further advice on troubleshooting your viewing problems. -
No luck yet? More tips for troubleshooting viewing issues
-
Contact HST Support access@hstalks.com
-
Please review our troubleshooting guide for tips and advice on resolving your viewing problems.
-
For additional help, please don't hesitate to contact HST support access@hstalks.com
We hope you have enjoyed this limited-length demo
This is a limited length demo talk; you may
login or
review methods of
obtaining more access.
- Biochemistry
-
1. De novo designed proteins: a breakthrough in snakebite treatment
- Dr. Susana Vazquez Torres
- Cancer/Oncology
-
2. From lab to clinic: bridging cancer genetics and public health
- Prof. Clare Turnbull
-
3. Engineered yeast: a breakthrough in targeted cancer therapies
- Prof. Gautam Dantas
-
5. Cancer vaccines
- Dr. Elias Sayour
-
6. The future of blood tests in cancer treatment
- Dr. Isaac Garcia-Murillas
-
8. Artificial intelligence in precision medicine
- Dr. Michael P. Menden
-
9. How liver X receptor regulates intestinal regeneration and tumor growth
- Dr. Srustidhar Das
- Immunology & Inflammation
-
10. Role of ETS2 in autoimmune and inflammatory diseases
- Dr. James Lee
-
11. Rheumatic diseases and musculoskeletal pain
- Prof. Anisur Rahman
-
13. Transmembrane domains and the regulation of trogocytosis in T cells
- Dr. Stefano Barbera
- Infectious Diseases/Microbiology
-
15. Elite controllers of HIV: from discovery to future therapies
- Prof. Bruce Walker
-
17. Towards developing a universal influenza vaccine
- Prof. Peter Palese
- Methods
-
19. The role of preregistration and registered reports in improving research transparency and reproducibility
- Dr. Peter Bonde Ernst-Rasmussen
-
20. Decoding aging: how a proteomic clock predicts mortality and disease across populations
- Dr. M. Austin Argentieri
-
21. MassBank development and future
- Dr. Emma L. Schymanski
-
22. Synthetic whole embryo models and their applications
- Prof. Jacob (Yaqub) Hanna
-
23. Pioneering proteomics: insights on advancements in the science of proteins
- Prof. Ruedi Aebersold
- Neurology/Neuroscience
-
24. Rethinking the amyloid dogma in Alzheimer’s disease
- Prof. George Perry
-
25. Integrated multimodal cell atlas of Alzheimer’s disease
- Dr. Michael Hawrylycz
-
26. How and why neurons die in Alzheimer's disease?
- Prof. Bart De Strooper
-
27. Restoring glucose metabolism: a new approach to reversing cognitive decline in AD
- Prof. Katrin Andreasson
-
28. Advancing ALS genetics through accessible testing
- Dr. Teresa Fecteau
-
29. MicroRNA as a biomarker for early detection of amyotrophic lateral sclerosis
- Dr. Sandra Banack
- Dr. Paul Alan Cox
- Dr. Rachael Dunlop
-
30. Translational research in amyotrophic lateral sclerosis (ALS)
- Prof. Aaron D. Gitler
-
31. Muscarinic acetylcholine receptor modulation in neurological diseases
- Prof. Andrew B. Tobin
- Pharmaceutical Sciences
-
32. The state of the art in secondary pharmacology
- Dr. Jean-Pierre Valentin
-
33. The safety, toxicology, and regulation of antibody-drug conjugates
- Dr. Veysel Kayser
-
35. Management of generic drug development: challenges and opportunities
- Mr. Sandeep Patil
-
36. Translational medicine: the risk of failure in delay and how to reduce it
- Prof. Martin Wehling
-
37. Artificial intelligence in guiding cancer treatment decisions
- Prof. Eytan Ruppin
-
38. The regulation of cell therapy
- Prof. Moutih Rafei
-
39. Scale-up challenges in the production of nanomedicines from lab to industry
- Prof. Dr. Oya Tagit
-
40. Challenges and solutions of scaling up
- Dr. Shaukat Ali
-
42. Using real-world insights on drug interactions to inform drug development
- Dr. Amita Datta-Mannan
-
43. Role of marketing authorization holder in drug safety
- Dr. Raphael Elmadjian Pareschi
Topics Covered
- De novo protein design
- Snakebite envenoming & antivenom development
- Computational protein engineering
- Deep learning tools
- In vitro and in vivo validation
- Global health and democratization of drug discovery
Biography
Dr. Susana Vazquez Torres is a protein design researcher in the Department of Biochemistry at the University of Washington School of Medicine, USA, where she works in the laboratory of Prof. David Baker, the 2024 Nobel Prize in Chemistry laureate. Her work combines computational and experimental approaches to engineer novel proteins, including high-affinity binders and molecules with potential applications in diagnostics, therapeutics, and neglected diseases.
Links
Series:
Categories:
Therapeutic Areas:
External Links
Talk Citation
Vazquez Torres, S. (2026, March 31). De novo designed proteins: a breakthrough in snakebite treatment [Audio file]. In The Biomedical & Life Sciences Collection, Henry Stewart Talks. Retrieved April 18, 2026, from https://doi.org/10.69645/VRTV3682.Export Citation (RIS)
Publication History
- Published on March 31, 2026
Financial Disclosures
- Dr. Susana Vazquez Torres has not informed HSTalks of any commercial/financial relationship that it is appropriate to disclose.
Audio Interview
De novo designed proteins: a breakthrough in snakebite treatment
Published on March 31, 2026
8 min
A selection of talks on Biochemistry
Transcript
Please wait while the transcript is being prepared...
0:00
Interviewer: We're joined
today by Susana Vazquez Torres
to discuss her
recent Nature paper,
which was published together
with her colleagues
at the lab of Prof. David Baker,
recipient of the Nobel
Prize in chemistry in 2024.
The paper describes a
successful engineering
of the novel proteins
that are capable of
efficiently neutralizing
little snake venom toxins.
Susana, thank you so much
for joining us today.
Dr. Vazquez Torres: Thank you
so much for the invitation.
Interviewer: Can you start
by sharing with us the need
that you've identified
and the approach
that you've undertaken
to address it?
Dr. Vazquez Torres: We were
interested in working on
snakebite envenoming
because it's a huge
problem worldwide
as it leads to a big number
in mortality and morbidity,
and the current treatments
are not very good.
They address this problem.
But there are so many things
that can be improved,
and we thought that
with protein design,
we could make these
treatments much more safer,
more affordable,
and more effective.
Interviewer: What were the
key challenges in your approach
and how did you overcome them?
Dr. Vazquez Torres: One of
the big challenges that we had
was to design proteins with
high affinity and specificity.
But not only that, we also
wanted to design proteins
that were able to neutralize
toxins in vitro and in vivo.
Those are two
different challenges.
But we were very
lucky and privileged
as we used these novel
protein design methods
that are very accurate to
design these proteins.
Even if the challenge
was very big,